RT Journal Article
SR Electronic
T1 <sup>64</sup>Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1869
OP 1875
DO 10.2967/jnumed.112.118612
VO 54
IS 11
A1 Tamura, Kenji
A1 Kurihara, Hiroaki
A1 Yonemori, Kan
A1 Tsuda, Hitoshi
A1 Suzuki, Junko
A1 Kono, Yuzuru
A1 Honda, Natsuki
A1 Kodaira, Makoto
A1 Yamamoto, Harukaze
A1 Yunokawa, Mayu
A1 Shimizu, Chikako
A1 Hasegawa, Koki
A1 Kanayama, Yousuke
A1 Nozaki, Satoshi
A1 Kinoshita, Takayuki
A1 Wada, Yasuhiro
A1 Tazawa, Shusaku
A1 Takahashi, Kazuhiro
A1 Watanabe, Yasuyoshi
A1 Fujiwara, Yasuhiro
YR 2013
UL http://jnm.snmjournals.org/content/54/11/1869.abstract
AB The purpose of this study was to determine the safety, distribution, internal dosimetry, and initial human epidermal growth factor receptor 2 (HER2)–positive tumor images of 64Cu-DOTA-trastuzumab in humans. Methods: PET was performed on 6 patients with primary or metastatic HER2-positive breast cancer at 1, 24, and 48 h after injection of approximately 130 MBq of the probe 64Cu-DOTA-trastuzumab. Radioactivity data were collected from the blood, urine, and normal-tissue samples of these 6 patients, and the multiorgan biodistribution and internal dosimetry of the probe were evaluated. Safety data were collected for all the patients after the administration of 64Cu-DOTA-trastuzumab and during the 1-wk follow-up period. Results: According to our results, the best timing for the assessment of 64Cu-DOTA-trastuzumab uptake by the tumor was 48 h after injection. Radiation exposure during 64Cu-DOTA-trastuzumab PET was equivalent to that during conventional 18F-FDG PET. The radioactivity in the blood was high, but uptake of 64Cu-DOTA-trastuzumab in normal tissues was low. In 2 patients, 64Cu-DOTA-trastuzumab PET showed brain metastases, indicative of blood–brain barrier disruptions. In 3 patients, 64Cu-DOTA-trastuzumab PET imaging also revealed primary breast tumors at the lesion sites initially identified by CT. Conclusion: The findings of this study indicated that 64Cu-DOTA-trastuzumab PET is feasible for the identification of HER2-positive lesions in patients with primary and metastatic breast cancer. The dosimetry and pharmacologic safety results were acceptable at the dose required for adequate PET imaging.